MannKind (NASDAQ:MNKD - Get Free Report) is anticipated to post its Q1 2025 quarterly earnings results before the market opens on Thursday, May 8th. Analysts expect MannKind to post earnings of $0.03 per share and revenue of $75.86 million for the quarter.
MannKind (NASDAQ:MNKD - Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The biopharmaceutical company reported $0.04 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.03 by $0.01. MannKind had a negative return on equity of 17.74% and a net margin of 8.07%. During the same quarter in the prior year, the business earned $0.05 earnings per share. The firm's quarterly revenue was up 18.1% compared to the same quarter last year. On average, analysts expect MannKind to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.
MannKind Trading Down 6.4 %
MNKD stock traded down $0.31 during trading on Thursday, hitting $4.54. The company had a trading volume of 790,577 shares, compared to its average volume of 2,375,368. MannKind has a one year low of $4.17 and a one year high of $7.63. The business has a 50-day moving average of $4.91 and a 200-day moving average of $5.86. The stock has a market cap of $1.38 billion, a PE ratio of 64.86 and a beta of 1.14.
Analyst Upgrades and Downgrades
A number of research firms recently weighed in on MNKD. Mizuho began coverage on MannKind in a research note on Thursday, April 10th. They set an "outperform" rating and a $12.00 price target on the stock. StockNews.com upgraded MannKind from a "hold" rating to a "buy" rating in a report on Wednesday, March 19th. Finally, Wedbush restated an "outperform" rating and set a $11.00 price objective on shares of MannKind in a report on Thursday, February 27th. Eight equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company's stock. Based on data from MarketBeat, the company currently has a consensus rating of "Buy" and an average target price of $9.56.
Read Our Latest Report on MNKD
MannKind Company Profile
(
Get Free Report)
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults.
See Also
Before you consider MannKind, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MannKind wasn't on the list.
While MannKind currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
